Stock Taper
SCREENER COMPARE ANY 2 STOCKS
GTBP
GT BIOPHARMA, INC.
NASDAQ
$0.30
▼ DOWN 0.60% (-0.00)

KEY STATISTICS

Market Cap$9.47 M
52w High$1.37
52w Low$0.26
Dividend Yield—
Frequency—
P/E-0.08
Volume373.84K
Shares Out.31.55M

COMPANY

LEADERSHIP

Michael Martin Breen
CHIEF EXECUTIVE
Michael Martin Breen

COMPENSATION 2026

Salary$641,020
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$159,569
Total$1,727,646

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 27, 2018
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
1

UPCOMING EARNINGS

DateNov 13, 2026
DayFriday
Rev. Est.—
NOV
13
FRI

SPLIT RECORD

DATETYPERATIO
2024-02-05Reverse1:30
2021-02-11Reverse1:17
2017-08-21Reverse1:300
2015-12-15Reverse1:250
1998-10-21Reverse1:5

PRICE

$0.30 ▼ DOWN 0.60% (−$0.00)
OVERLAYS
$0.30$0.30$0.31$0.319:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM0.30

About GT Biopharma, Inc.

https://www.gtbiopharma.com ↗

GT Biopharma, Inc. is a clinical-stage biopharma developing immuno-oncology products using TriKE technology, with several candidates in clinical and preclinical trials targeting various cancers.

INDUSTRY

Biotechnology

A PRODUCT GT BIOPHARMA, INC. IS KNOWN FOR

GTB-5550 TriKE®
GTB-5550 TriKE®

GTB-5550 is a B7-H3-targeted TriKE® therapy for solid tumors like prostate, ovarian, and lung cancers, recently FDA-cleared for Phase 1 trials, marking a key milestone in the company's development pipeline.

COMPETITORS

COMPETITOR
FATE COMPARE
IBRX COMPARE
NKTX COMPARE
XNCR COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
VXF
0.00% · 376.4K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
3.94%
HOLDERS
82
TOP 12 OF 82 · RANKED BY POSITION SIZE
Geode Capital Management, LLC
294.5K sh · $120.17K
Drw Securities, LLC
142.4K sh · $83.5K
Hrt Financial LP
107.1K sh · $52K
Everhart Financial Group, Inc.
100.0K sh · $48.97K
Srs Capital Advisors, Inc.
93.6K sh · $45.85K
Bank Of Montreal /Can/
92.5K sh · $54.59K
Opal Wealth Advisors, LLC
81.8K sh · $40.06K
Citadel Advisors LLC
80.8K sh · $63.41K
Northern Trust Corp
75.5K sh · $36.95K
49 Wealth Management, LLC
64.0K sh · $31.34K
Cetera Investment Advisers
55.9K sh · $27.39K
Scientech Research LLC
54.7K sh · $42.99K

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF FINANCIAL OFFICER
URBAN ALAN LOUIS
Purchase · 50.0K shares
2025-09-04
★
DIRECTOR, OFFICER: CEO AND DIRECTOR
Breen Michael Martin
Purchase · 100.0K shares
2025-09-04
★
DIRECTOR
Mun-Gavin David C.
Purchase · 31.3K shares
2025-09-04
★
DIRECTOR
CASAMENTO CHARLES J
Purchase · 62.5K shares
2025-09-04

SECTORS PEERS

PEERPRICE
REVB$1.05COMPARE
ARTL$0.66COMPARE
PTIX$0.98COMPARE
DRMA$1.34COMPARE
SLXN$0.36COMPARE
PBM$4.21COMPARE
CARM$0.00COMPARE
WINT$0.00COMPARE